SID update uncovers new immune reset insights into ITK inhibition

Research evidence excerpt

SID update uncovers new immune reset insights into ITK inhibition

May 14, 2026

inhibitor, PFE, N covered by C. Gould) and Rinvoq (JAK inhibitors, ABBV,

OW, covered by C. Gould) also show rapid rebounds within 1-4 weeks

of treatment discontinuation.

●One nitpicking pushback is that the placebo arm also didn't rebound

off-treatment (after EASI score reduction).

Mechanistic data support immune remodeling, not just cytokine

suppression

●Corvus presented deeper translational data using single-cell RNA

sequencing, flow cytometry, and serum cytokines to characterize

treatment-related changes in cytokine signaling, immune cell

transcriptional programs, and circulating immune cell populations.

●The results suggest a potential immune remodeling in patients with a

decrease in Ki67 high Th2 cells (activated/proliferating) and a sustained

increase in Tregs.

●The Tregs that are primed by SQL express BACH2, which is a marker

of durable stable Treg (Roychoudhuri, Nature, 2013). This could be a

key driver of durable response observed.

●From the single-cell RNA sequencing, Corvus uncovered that the

changes in T cell transcription with SQL induce an expression of SOCS3,

which in part inhibits the JAK/STAT pathway indirectly.

●The serum cytokine data is the "noisier" part of the data set, with

high variations on and off treatments and varies. But this is typical of

serum cytokine readouts; the scRNA-seq and flow cytometry data paint

a cleaner picture.

●The updated data supports the idea that SQL could be a pipeline in a

product with relevance beyond AD. Corvus plans to initiate a trial in

Hidradenitis Suppurativa (HS, Th17 driven) and asthma, which is (Th2

driven).

Safety remains very clean compared to placebo

●Corvus presented a complete adverse event table. There were no